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Foamy viruses (FV) are retroviruses that are widely distributed in primate and non-primate animal
species. We tested here FV with capsids of simian and non-simian origin for sensitivity to interferon-β
(IFN-β). Our data show signiﬁcant inhibition of FV by IFN-β early in infection of human HOS and THP-1
but not of HEK293T cells. The post-entry restriction of FV was not mediated by the interferon-induced
MxB protein that was recently identiﬁed as a capsid-interacting restriction factor targeting Human
immunodeﬁciency virus (HIV) before integration. Neither the ectopic expression of MxA or MxB in
HEK293T cells nor the lack of MxB expression in CRISPR/CAS MxB THP-1 knockout cells impacted the
infection of the tested FV. IFN-β treated THP-1 and THP-1 KO MxB cells showed the same extend of
restriction to FV. Together, the data demonstrate that IFN-β inhibits FV early in infection and that MxB is
not a restriction factor of FV.
& 2015 Published by Elsevier Inc.Introduction
Foamy viruses (FVs; also known as spumaviruses) belong to
Retroviridae but display several unique features in their repli-
cation strategy and therefore constitute the only genus in the
Spumaretrovirinae subfamily (Linial et al., 2005). Infectious FVs
were isolated from prosimians, New and Old world monkeys,
apes, tree shrews, bats, cats, cows, sea lions and horses (for
recent reviews see Kehl et al., 2013; Rethwilm and Bodem, 2013).
Endogenized copies of FV genomes were identiﬁed in sloths, the
Aye-Aye, the cap golden mole, cod, platyﬁsh, zebra ﬁsh and the
coelacanth (Han and Worobey, 2012a, 2012b;
Katzourakis et al., 2014, 2009; Llorens et al., 2009; SchartlMedical Faculty Carl Gustav
4, 01307 Dresden, Germany.
x: þ49 211 81 18752.
(D. Lindemann),
e and are co-ﬁrst authors.et al., 2013). Thus, FVs are ubiquitously present in animals and
seem to have co-evolved with their natural hosts for a very long
time. Especially, simian foamy viruses (SFVs) were intensively
studied to be non-pathogenic retroviruses that infect many pri-
mates (Rua and Gessain, 2015). Zoonotic apathogenic infections
by SFVs are well documented. However, humans are dead-end
hosts, no human-to-human transmissions were observed (for
reviews see Khan, 2009; Locatelli and Peeters, 2012; Mouinga-
Ondeme and Kazanji, 2013). Previous work showed that inter-
ferons can inhibit the spreading replication of the prototype
foamy virus (PFV), a chimpanzee isolate and other SFVs (Falcone
et al., 1999; Matthes et al., 2011; Rhodes-Feuillette et al., 1990,
1987; Sabile et al., 1996). Furthermore, a few cellular restriction
factors such as various APOBEC3 proteins or Trim5α have been
reported to restrict FVs in a species-dependent manner (Chareza
et al., 2012; Jaguva Vasudevan et al., 2013; Löchelt et al., 2005;
Lukic et al., 2013; Pacheco et al., 2010; Perkovic et al., 2009;
Russell et al., 2005; Yap et al., 2008).
The human myxovirus B (MxB, Mx2) dynamin-like GTPase
was recently identiﬁed as a restriction factor for human
A. Bähr et al. / Virology 488 (2016) 51–6052immunodeﬁciency virus (HIV) (Fricke et al., 2014; Goujon et al.,
2013; Kane et al., 2013; Liu et al., 2013; Matreyek et al., 2014).
Humans also encode the homolog (out-paralog) MxA (Mx1).
The genes for MxA and MxB are under positive selection, pos-
sibly indicating species-speciﬁc interactions with pathogens
(Busnadiego et al., 2014; Mitchell et al., 2012; Sironi
et al., 2014). While Mx1 and Mx2 genes are found in most
mammals, a few notable exceptions were identiﬁed: Toothed
whales lost both genes and rodents and felids lost the ortholog
of human Mx2 (Braun et al., 2015; Busnadiego et al., 2014).
Both, MxA and MxB genes are inducible by interferon-α/-β
and thus belong to the group of interferon-stimulated genes
(ISGs). At the protein level MxA and MxB show an identity of
56% where the N-terminal protein regions have the largest
diversity and share only 8% identical residues. Mx proteins
constitute a distinct subclass among the IFN-inducible GTPase
superfamily in humans that includes the IRG-, GBP- and GVIN-
subfamilies (Kim et al., 2012). MxA and MxB proteins have
extranuclear cytoplasmic localization; MxB additionally is
concentrated at the cytoplasmic face of nuclear pores (Brantis-
de-Carvalho et al., 2015; Fricke et al., 2014; Goujon et al., 2014;
Kane et al., 2013; King et al., 2004; Staeheli and Haller, 1985).
MxA proteins are antiviral against many viruses, such as ortho-
myxoviruses (e.g. Thogoto virus and Inﬂuenza A virus), bunya-
viruses (e.g. Crimean-congo hemorrhagic fever virus), rhabdo-
viruses (e.g. Vesicular stomatitis virus, VSV), and hepadnaviruses
(e.g. Hepatitis B virus) (for review and complete list, see Haller and
Kochs, 2011; Haller et al., 2015). Human MxA restricts these viruses
either by targeting the viral nucleocapsids and preventing their
nuclear import or by inhibition of early viral mRNA synthesis or by
sequestering of newly synthesized viral protein into perinuclear
complexes (Haller et al., 2015). Inﬂuenza viruses can escape from
this restriction through adaptive mutations in the nucleoprotein
(Manz et al., 2013).
MxB was considered to have functions different from being
a major restriction protein (King et al., 2004), as MxBs of cows,
water buffaloes, pigs and humans were identiﬁed to be weakly
antiviral only against VSV (Babiker et al., 2007; Liu et al., 2012;
Sasaki et al., 2014). However, several recent publications prove
that MxB blocks HIV-1 replication at a late post-entry step after
reverse transcription affecting viral uncoating and interfering
with nuclear entry and maybe post-nuclear trafﬁcking and/or
with integration (Fricke et al., 2014; Goujon et al., 2013; Kane
et al., 2013; Liu et al., 2013; Matreyek et al., 2014; Schulte
et al., 2015). Human MxB restricts in addition to HIV-1, HIV-2,
SIVs and the betaretrovirus Mason-Pﬁzer monkey virus (M-
PMV), but has no or a very modest effect on human endogenous
virus type K (HERV-K), feline immunodeﬁciency virus (FIV),
equine infectious anemia virus (EIAV) or murine leukemia virus
(MLV) (Busnadiego et al., 2014; Fricke et al., 2014; Goujon et al.,
2013; Kane et al., 2013; Liu et al., 2013; Matreyek et al., 2014).
MxB proteins isolated from dog and sheep neither inhibit HIV-
1 nor HERV-K, FIV, EIAV, MLV or M-PMV (Busnadiego et al.,
2014). HIV-1 capsid mutations especially in the cyclophilin A
binding loop that alter the nuclear entry pathway relieve the
inhibition by MxB (Busnadiego et al., 2014; Goujon et al., 2013;
Kane et al., 2013; Liu et al., 2013, 2015; Matreyek et al., 2014),
as well as mutations in integrase confer resistance (Matreyek
et al., 2014).
Here we asked whether the type I IFN induced block of FV
replication is mediated by the IFN-induced MxB protein as
reported for HIV-1.Results
Foamy viruses of diverse origin are inhibited by IFN-β in a cell-type
dependent manner
To test whether foamy viruses are sensitive to interferon during
the early phase of infection, human HEK293T and HOS cells were
treated with interferon-β (IFN-β) for 24 h and subsequently
transduced by a range of β-galactosidase-encoding single-round
replicating foamy virus reporter vectors. In this system, we
included the prototype foamy virus (PFV), vectors based on diverse
simian FV (SFV) from African green monkey (SFVagm), from
macaque (SFVmac), from marmoset (SFVmar), from orangutan
(SFVora), from spider monkey (SFVspm), from squirrel monkey
(SFVsqu), and bovine foamy virus (BFV) and the feline foamy virus
(FFV). All the foamy viral vectors transduced an identical PFV-
derived vector with LacZ-reporter gene cassette but differed in
their viral Gag structural proteins, except FFV vector particles,
which transduced the identical LacZ-reporter gene cassette, but
was completely derived from FFV virus components. Applying the
highest dose of IFN-β (1000 U/ml) infected HEK293T cells showed
a weak inhibition of 10–15% in four of the nine tested FVs (SFVora,
SFVspm, SFVsqu and FFV) compared to respective IFN-untreated
cells (Fig. 1A). In contrast, restriction of FVs by IFN-β was much
stronger and broader in HOS cells. PFV, SFVagm, SFVmac, SFVmar,
SFVsqu, BFV and FFV were inhibited by 50–60%, and SFVora and
SFVspm by up to 90% (Fig. 1B). In HOS cell infections, 100 U/ml
IFN-β was as antiviral as 1000 U/ml IFN-β. β-galactosidase detec-
tion of the vector-transduced cells using a chemiluminescence
detection system stayed within the dynamic range for all applied
vector concentrations for all infections. Titration of PFV stocks on
HOS cells demonstrated linearity for applied vector concentrations
(Fig. 1C).
We speculated that IFN-treated HOS but not HEK293T cells
might restrict the early phase of FV infection due to MxB protein
expression as shown for HIV-1. Indeed, immunoblots of IFN-β
treated HOS cells demonstrated the induction of MxB restriction
factor (Fig. 1D). Moreover, HOS cells not treated with IFN-β and
HEK293T with and without IFN-induction did not express
detectable MxB protein. Finally, we wanted to examine whether
IFN-β is a physiological relevant agent to induce MxB in primary
human cells. Monocyte derived macrophages (MDM) and mono-
cyte derived dendritic cells (MDDC) were incubated with IFN type
I and type II for 24 h and analyzed for MxB by immuno blots
(Fig. 2A and B). In fact, in MDMs of two different donors, IFN-β
induced higher MxB levels than IFN-α2a/-α2b or IFN-γ. IFN-γ was
able to induce a weak level of MxB only in MDMs of donor 2. In
MDDC, both, IFN-β and IFN-α2a induced high amounts of MxB,
whereas CCL19, CXCL10, TNF-α or IFN-γ did not induce MxB
expression in MDDC.
Foamy viruses are resistant to MxB
To test whether MxA or MxB proteins could be involved in FV
restriction seen in IFN-treated HOS cells, we generated HEK293T
cells with stable expression of MxA and MxB (HEK293T-MxA,
HEK293T-MxB) (Fig. 3A). The functional characterization of the Mx
expressing cell lines was done by infections with lentiviral luci-
ferase reporter vectors based on HIV-1, HIV-2, Simian immuno-
deﬁciency virus (SIV) from macaques (SIVmac), SIV from African
green monkeys (SIVagm), FIV and EIAV. We found that HIV-1 and
SIVmac were inhibited by up to 80% by MxB. Around 50% inhibi-
tion by MxB was observed using HIV-2, SIVagm and FIV. EIAV was
not inhibited. These observations conﬁrmed results recently
reported (Fricke et al., 2014; Goujon et al., 2013; Kane et al., 2013;
Liu et al., 2013; Matreyek et al., 2014). Whether MxA can inhibit
Fig. 1. Interferon inhibits foamy virus transduction in a cell-type dependent manner. (A) HEK293T and (B) HOS cells were treated with IFN-β (100 U/ml or 1000 U/ml) for
24 h and then infected with different foamy virus LacZ reporter vectors for 72 h. Relative β-galactosidase activities to infections without IFN-β are displayed, asterisks
represent statistically signiﬁcant differences: ***, Po0.001; **, P¼0.001–0.01; *, P¼0.01–0.05; ns, P40.05 [Dunnett t test]. (C) Reporter activity of decreasing amounts of PFV
vectors on HOS cells. Virus dilutions 1:5, 1:50, 1:500. (D) MxB expression of IFN-β treated HEK293T and HOS cells in comparison to monocyte derived macrophages (MDM)
and HEK293T cells stable expressing MxA or MxB. MxB expression was detected by immunoblotting with anti-MxB antibody. Cell lysates were also analyzed for equal
amounts of total proteins by using anti-tubulin antibody. cps, counts per second. PFV, prototype foamy virus (FV); BFV, bovine FV; SFVagm, simian FV (SFV) from African
green monkey; SFVmac, SFV from macaques; SFVmar, SFV from marmoset; SFVora, SFV from orangutan; SFVspm, SFV from spider monkey; SFVsqu, SFV from squirrel
monkey; FFV, feline FV.
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most of the tested lentiviruses (Fig. 3B). HIV-1 showed resistance
to MxA, as reported before (Goujon et al., 2014; Goujon et al.,
2013). Similar, HIV-2, SIVagm, FIV and EIAV were not inhibited.
However, SIVmac showed 20% repression by MxA, indicating that
MxA has some residual antiviral activity against some lentiviruses.
A titration experiment with HIV-1 on MxB expressing cells
demonstrated that the MxB restriction is not saturated by too high
amounts of infecting viruses or lost by too low numbers of parti-
cles. We applied HIV-1 particles equivalent to 0.22 pg to more than
500 pg reverse transcriptase activity and detected a linear corre-
lation of determined viral transferred luciferase activity for infec-
tions in cells that express or do not express MxB (Fig. 3C). Over this
range of viral inocula, the factor of restriction was nearly identical
(Fig. 3D). Neither very low number nor very high number of HIV-1
particles escaped the MxB-mediated restriction.
In the next experiments, the Mx expressing cells were incu-
bated with FV vectors and transgenic β-galactosidase activity was
measured. The results show that HEK293T cells expressing MxA or
MxB did not restrict infection of FV (Fig. 4A). Moreover, HEK293T
cells expressing Mx proteins showed higher reporter vector
expression, depending on the FV Gag species used from around
10% (e.g. SFVmac) up to 40% (e.g. FFV) and BFV showed an
exceptional 80% higher expression in HEK293T-MxB cells. The
infection of Mx expressing cells prestimulated with IFN-β did not
enhance the restriction of Mx proteins (Fig. 4B). While the reason
for enhanced transduction of HEK293T-MxA or -MxB cells by FV
was not investigated, the data strongly indicate lack of Mx-protein
repression of FV and that IFN-β treatment of HEK293T does not
induce a factor that would sensitize FV for Mx proteins.Foamy viruses infect THP-1 cells and THP-1 MxB KO cells equally
Endogenous MxB protein in myeloid cells could be more anti-
viral active against FVs than ectopic expressed MxB in HEK293T
cells. To investigate this question, we infected the human mono-
cytic cell line THP-1 with and without IFN-β pretreatment and
measured viral β-galactosidase. THP-1 cells demonstrated induc-
tion of MxA and MxB by IFN-β treatment and untreated cells
lacked detectable amounts of Mx proteins (Fig. 5A). In a pilot
experiment we wanted to know, whether the antiviral activity of
IFN-β to FVs on THP-1 cell infection would depend on the titer of
the viral inoculum. THP-1 cells were prestimulated with INF-β
(1000 U/ml) and infected with serial dilutions of PFV. Over the
whole range of the tested virus dilutions, IFN induced a 70%
inhibition of the reporter virus (Fig. 5B). This data shows, that high
and low titers of FVs are equally sensitive to IFN-β in THP-1 cells.
Next we compared different FVs in this experimental system. IFN-
β (1000 U/ml) treatment of THP-1 cells restricted all FVs except
FFV similar as before in HOS cells. PFV, SFVmac, SFVmar, SFVspm,
SFVsqu were inhibited by IFN-β by 80–90%, a strength of inhibition
similar found for HIV-1 (Fig. 5C). BFV, SFVagm and SFVora showed
60–70% inhibition by IFN-β on THP-1 cells. In a next experiment,
we examined THP-1 cells that lost the expression of MxB due to a
CRISPR/CAS9-mediated inactivation of the MxB gene, here referred
to as THP-1 KO MxB cells. THP-1 KO MxB cells showed only MxA
expression after IFN-β treatment (Fig. 5A). To test whether THP-1
WT or KO MxB cells are equally infectable over a range of virus
dilutions, we performed a serial dilution using PFV (Fig. 5D and E).
These infections revealed that the WT and MxB knockout cells
were similar infectable. In addition, we treated both cell lines with
IFN-β (1000 U/ml) before infection. IFN-treatment inhibited the
A. Bähr et al. / Virology 488 (2016) 51–6054PFV transduction. To compare PFV to other FVs, THP-1 KO MxB
cells were infected with various FVs in the presence or absence of
IFN-β (Fig. 5F). IFN-β treatment restricted FVs with a very similar
strength in both WT THP-1 cells (Fig. 5C) and MxB KO cells
(Fig. 5F), indicating that MxB is not important for interferon-Donor 1 Donor 2
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of 0.22 pg to 500 pg RT. (D) Same experiment as in (C), with data of MxB restriction shinduced inhibition of FVs and that MxB is not a restriction factor
for these viruses.
Taken together, neither ectopic nor interferon-induced endo-
genous MxB protein inhibits the early infection of foamy viruses.
IFN targets Gag and Pol of foamy viruses
As FV perform reverse transcription mainly during virus mor-
phogenesis and not upon infection of target cells, ISGs probably
inhibit other steps of the FV transduction. For further elucidation
of the differences in IFN sensitivity between PFV and FFV, we
generated a set of different four-component FV vector particles,
containing the same PFV-based vector genome encoding the LacZ
reporter gene cassette and SFVmac glycoprotein but varying in
their Gag and Pol composition as indicated in Fig. 6A and exam-
ined their sensitivity towards IFN. Characterization of the nucleic
acid composition of the individual viral particle preparations
revealed similar viral genome RNA (vRNA) and beta-actin mRNA
(hACTB mRNA) content in all samples containing viral particles
(Fig. 6B). In contrast, large differences in viral DNA (vDNA) content
were observed, in particular FVs with chimeric Gag and Pol protein
composition. However, although intra-particle genome reverse
transcription in these mutant particles was strongly diminished it
was not completely abolished as revealed by the comparison to
PFV particles containing enzymatic inactive RT (PFV wt/iRT). Taken
together these data indicates similar vRNA and cellular RNA
encapsidation features of the different FVs and suggest a limited
functional compatibility of Gag and Pol proteins from primate and
non-primate FV species.
PFV vectors with enzymatic inactive RT (PFV wt/iRT) are known
to just transfer RNA that is capable of being translated transiently
in the transduced cells. In contrast, FV vectors with enzymatic
inactive integrase (PFV wt/iIN) still reverse transcribe the encap-
sidated viral RNA into DNA but have a strongly reduced integration
potential and display a predominantly transient expression from
episomal viral DNA genomes (Hamann et al., 2014b). Both type of
viruses showed LacZ activity signals in transduced THP-1 cells at
levels only slightly above that of uninfected cells or cells exposed140
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samples was not signiﬁcantly altered by IFN addition. In contrast,
cells transduced with wild type PFV particles (PFV wt/wt) showed
a strong reduction in LacZ activity upon IFN addition, which was
further pronounced by transduction with SFVspm Gag containing
viruses (PFV spm/wt) (Fig. 6C and D). In contrast, the IFN sensi-
tivity of LacZ activity in cells transduced with either FFV Gag (PFV
ffv/wt) or FFV Pol (PFV wt/ffv) containing particles was diminished
in comparison to wild type PFV particle (PFV wt/wt) transduced
cells (Fig. 6C and D). The infection of target cells with viruses
harboring a combination of FFV Gag and Pol, either together with a
PFV (PFV ffv/ffv) or FFV (FFV ffv/ffv) vector genome, resulted in a
complete resistance of LacZ activity towards IFN inhibition (Fig. 6C
and D).
Together the data strongly suggest that in THP-1 cells the ISGs
target the Gag and the Pol proteins separately. IFN does not inhibit
the translation of FV vectors. Furthermore, in PFV the integrase is a
key determinant for IFN sensitivity.Discussion
We show here that FVs carrying capsids derived from simian
and non-simian FVs are sensitive to interferon-β. The data prove
that interferon triggers a restriction that affects early steps of the
FV replication in human cells between entry and expression. MxB
was strongly induced by IFN-β in HOS and THP-1 cell lines as well
as in primary MDMs and MDDCs but not in HEK293T cells.
Apparently, the expression of MxB protein correlated with the IFN-mediated restriction of FV in HOS and THP-1 cells. Recently it was
discovered that primate lentiviruses, M-PMV and VSV can be
inhibited by MxB protein (Busnadiego et al., 2014; Fricke et al.,
2014; Goujon et al., 2013; Kane et al., 2013; Liu et al., 2012, 2013;
Matreyek et al., 2014). Thus, we speculated that MxB would be
involved in the IFN-mediated restriction of FVs. However, our
results indicate that neither the ectopic MxA or MxB expression
nor IFN-induced endogenous MxB presents a post-entry repressor
for FVs. The current model suggests, that MxB affects HIV-1
uncoating and nuclear entry through the nuclear pores, and pos-
sible intra-nuclear steps of HIV-1 replication (Busnadiego et al.,
2014; Fricke et al., 2014; Goujon et al., 2013; Kane et al., 2013; Liu
et al., 2013; Matreyek et al., 2014). Similar to HIV-1, the betare-
trovirus M-PMV was shown to be sensitive to MxB (Busnadiego et
al., 2014). While HIV-1 interacts with the nuclear envelope and can
infect non-dividing cells, it is not described if M-PMV requires cell
division for infection or is able to transduce resting cells. Thus,
based on the current knowledge it is unclear if sensitive lenti-
viruses and betaretroviruses are restricted by the same mechan-
ism by MxB.
We currently do not know why FVs are not inhibited by MxB.
FVs use pathways to enter the nucleus different than HIV-1 and
require target cell mitosis for productive infections (Bieniasz et al.,
1995). FVs infect non-dividing cells at a level intermediate
between gamma- and lentiviruses, but mitosis is required for
efﬁcient integration (Patton et al., 2004; Trobridge and Russell,
2004). Disassembly of FV capsids accumulating at the centrosome
in G0 resting cells is reported to be impaired and require cellular
stimulation to proceed (Lehmann-Che et al., 2007). However,
Fig. 5. MxB does not contribute to IFN-βmediated inhibition of foamy viruses. (A) THP-1WTand THP-1MxB CRISPR/CAS knockout cells (THP-1 KOMxB) were treated with IFN-β (1000 U/
ml). MxB expression was detected by immunoblotting with anti-MxB antibody and MxA expression was detected with an anti-Mx antibody. Cell lysates were also analyzed for equal
amounts of total proteins by using anti-tubulin antibody. (B) Serial dilutions of PFV vectors on THP-1 cells pretreated with IFN-β (1000 U/ml) or not treated. Relative β-galactosidase activities
to infections of the 1/5 dilution without IFN are displayed. (C) THP-1 WT cells were infected in the presence and absence of IFN-β with foamy viral vectors transducing LacZ and HIV-1
vectors transducing luciferase. Relative β-galactosidase or luciferase activities in the presence of IFN-β to infections without IFN-β in THP-1 WT cells are displayed, asterisks represent
statistically signiﬁcant differences: ***, Po0.001; **, P¼0.001–0.01; *, P¼0.01–0.05; ns, P40.05 [Dunnett t test]. (D, E) Infection of THP-1 WT cells (D) and THP-1 KO MxB cells (E) with
decreasing amounts of prototype foamy virus. Virus dilutions used: 1:5, 1:50, 1:500 and 1:5000, the 1:5 diluted virus was also tested on IFN-β treated cells. (F) THP-1 KO MxB cells were
infected in the presence and absence of IFN-β with foamy viral vectors transducing LacZ and HIV-1 vectors transducing luciferase. Relative β-galactosidase or luciferase activities in the
presence of IFN-β to infections without IFN-β in THP-1 KOMxB cells are displayed, asterisks represent statistically signiﬁcant differences: ***, Po0.001; **, P¼0.001–0.01; *, P¼0.01–0.05; ns,
P40.05 [Dunnett t test]. PFV, prototype foamy virus (FV); BFV, bovine FV; SFVagm, simian FV (SFV) from African greenmonkey; SFVmac, SFV frommacaques; SFVmar, SFV frommarmoset;
SFVora, SFV from orangutan; SFVspm, SFV from spider monkey; SFVsqu, SFV from squirrel monkey; FFV, feline FV; HIV-1, Human immunodeﬁciency virus type 1. cps, counts per second.
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Fig. 6. IFN targets Gag and Pol of foamy viruses. (A) List of different FV vectors (no. 1–9) tested with the individual characteristics in respect to FV species and nature of viral
nucleic acids, Gag, Pol and Env protein composition. (B) Nucleic acid composition of the individual FV preparations used for the analysis of IFN sensitivity in THP-1 cells
summarized in C and D. nd: not determined, due to incompatibility of qPCR primer probe sets used to the FFV genome. (C) Absolute β-galactosidase activities of THP-1 cells
infected with the FV vectors 1-9 listed in (A) in the absence or presence of IFN-β. (D) Relative β-galactosidase activities of the FV vectors 1–4 and 6–9 in the presence of IFN-β
(1000 U/ml) to infections without IFN-β in THP-1. Asterisks represent statistically signiﬁcant differences to non-transduced THP-1 cells: ***, Po0.001; **, P¼0.001–0.01; *,
P¼0.01–0.05; ns, P40.05 [Dunnett t test].
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G1/S arrested cells (Lo et al., 2010). Based on the latter observation,
it was proposed that FV preintegration complexes cross the intact
nuclear membrane similar to that of lentiviruses. Furthermore, FVs
reverse transcribe their packaged RNA genome to a signiﬁcant
extent already during virus assembly. The resulting viral DNA of FV
particles is thought to represent the main contributor for pro-
ductive target cell infection (Berka et al., 2013). However, addi-
tional reverse transcription, probably of viral RNA containing
particles taken up by infected host cells, was also observed in early
phases of FV infection, although its contribution to virus titers is
discussed controversial (Delelis et al., 2003; Zamborlini et al.,
2010). MxB needs to interact with the HIV-1 capsid protein to
restrict the virus (Buffone et al., 2015; Fricke et al., 2014; Liu et al.,
2015; Schulte et al., 2015). According to this model, we would
predict that FV capsid proteins which unlike their orthoretroviral
analogs demonstrate only a very limited proteolytic maturation
(Rethwilm and Lindemann, 2013), do not bind to MxB protein. We
disfavor a model in which FV express a counteractor of MxB,
because the tested primate and non-primate FVs are all resistant
and do not show sensitivity to human MxB. Indeed, viral coun-
teractors of cellular restriction factors are often species-speciﬁc
such as Vif- or Bet-mediated inhibition of antiviral APOBEC3 pro-
teins (Mariani et al., 2003; Perkovic et al., 2009).
Interferon can induce several hundred genes (Schneider et al.,
2014), thus, we propose that gene products other than MxB act
antiviral against FVs in our system. Why HEK293 cells reacted
differently to IFN-β than HOS and THP-1 cells and did not efﬁ-
ciently inhibit FVs is not clear, but may point to a cell-type speciﬁc
ISG expression in the three cell lines. Support for the relevance of
cell-type speciﬁc ISGs for FV restriction can be further concluded
from the different sensitivity of FFV to IFN. While FFV was only
weakly inhibited by IFN-β in HOS cells, IFN-treated THP-1 cellswere fully permissive to FFV, whereas the same cells strongly
repressed the other FVs tested. Initial experiments using chimeric
PFV/FFV virus particles suggested species speciﬁc contributions
towards IFN sensitivity of both FV Gag and Pol proteins.
Taken together, we conclude that type I IFN induces a cell-type
speciﬁc restriction of FVs that target FV Gag and Pol proteins
including the integrase.Material and methods
Plasmids
A four-component foamy virus (FV) vector system, consisting of
the expression-optimized packaging constructs pcoPG4 (PFV Gag),
pcoSE (SFVmac Env), pcoPP (PFV Pol) and its variants pcoPP2 (PFV
Pol iRT) or pcoPP3 (PFV Pol iIN) with enzymatic inactive reverse
transcriptase or integrase domains, as well the beta-galactosidase
(LacZ) protein-expressing PFV transfer vector pMD11, has been
described previously (Heinkelein et al., 2002; Maskell et al., 2015;
Mullers et al., 2011; Stirnnagel et al., 2010). Gag and Pol expressing
and LacZ reporter protein encoding two-component transfer vec-
tors of FFV (pcDWF002) origin are based on previously reported
EGFP-encoding variant pcDWF003 (Yap et al., 2008). FFV Gag
(p6iFG) and Pol (p6iFP) expressing packaging were generated by
subcloning the corresponding authentic FFV ORFs from pcDWF002
into the pUC19 based CMV-intron A driven eukaryotic expression
vector p6i. Expression-optimized ORFs for SFVmac (NC_010819),
SFVagm (NC_010820), SFVora (AJ544579), SFVmar (GU356395),
SFVsqu (GU356394), SFVspm (EU010385) and BFV (NC_001831)
were synthesized by Genscript (Piscataway, USA) and subc-
loned into the CMV-intron A driven eukaryotic expression vector
pczi (Heinkelein et al., 2002) and yielding in FV Gag packaging
A. Bähr et al. / Virology 488 (2016) 51–6058vectors pcziSFVmac coGag, pcziSFVagm coGag, pcziSFVor coGag,
pcziSFVmar coGag, pcziSFVsqu coGag, pcziSFVspm coGag, pcziBFV
coGag, respectively. HIV-1 vector pSIN.PPT.CMV.Luc.IRES.GFP
expresses the ﬁreﬂy luciferase and GFP. The luciferase cDNA (luc 3)
was cloned into NheI and BamH1 restriction sites of pSIN.PPT.
CMVmcsIRES.GFP (Kootstra et al., 2003), a gift of Neeltje Kootsta.
HIV-2 vector pHIV-2 Luc SV40 (old name pHIV-2 SEW Luc SV40)
expresses ﬁreﬂy luciferase. For cloning, in HIV-2-SEW (Kloke et al.,
2010) the EGFP cDNA was replaced with luciferase cDNA from
plasmid GL4.13 (Promega, Mannheim, Germany) using NheI x
XbaI. Human MxA and MxB were expressed by lentiviral vectors
pLVX-IRES-Puro (Takara Clontech, Saint-Germain-en-Laye, France).
The full-length ORF of human MxB (NM_002463) (Aebi et al.,
1989) was cloned into XhoI x NotI restriction sites to create pLVX-
IRES-Puro-MxB. The full-length ORF of MxA (NM_001178046) with
an N-terminal Flag epitope was cloned into the EcoRI x BamHI
restriction sites creating pLVX-IRES-Puro-FLAG-hsMxA.
Cell lines and interferon treatment
HOS (ATCC CRL-1543) and HEK293T (ATCC CRL-3216) cells
were maintained in Dulbecco's modiﬁed Eagle's medium complete
(PAN-Biotech, Aidenbach, Germany) and THP-1 (ATCC TIB-202) in
Roswell Park Memorial Institute (RPMI) 1640 medium (PAN-Bio-
tech) supplemented with 10% FBS, 0.29 mg/ml L-glutamine, and
100 U/ml penicillin/streptomycin at 37 °C in a humidiﬁed
atmosphere of 5% CO2. Stable Mx protein expression cell lines
were generated by transduction with HIV-1 vectors made by
transfection of pLVX-IRES-Puro or pLVX-IRES-Puro-MxB or pLVX-
IRES-Puro-FLAG-hsMxA together with psPAX2 (NIH AIDS Reagent
Program), pRSV-Rev (Dull et al., 1998) and pMD.G. Puromycin
resistant cell pools were tested for Mx protein expression by
immunoblots. MxB KO cells: MxB gene in THP-1 cells was inacti-
vated using CRISPR-Cas9 for genome engineering: The CRISPR
genomic guide RNA sequence (gRNA) to human MxB was taken
from a publically available resource described by Shalem et al.
(2014). The protocols used to characterize the gRNA were descri-
bed by Ran et al. (2013). The MxB gRNA oligo, target exon 2, were
annealed and ligated into pX330 (Cong et al., 2013), a construct
containing the gRNA cassette and Cas9 cDNA at Bbs1 restriction
sites. The selected MxB gRNA construct and CMV-GFPmax were
co-transfected into THP-1 cells using the Neon transfection system
(Life Technologies, Darmstadt, Germany). After 48 h of transfec-
tion, the cells were single cell sorted for GFPþ and PI- using the
FACSAria (BD Biosciences, Franklin Lakes, USA). Clonal THP-1
colonies were expanded and characterized for a loss of MxB pro-
tein expression. The MxB gRNA target sequences were
CCGCCATTCGGCACAGTGCC (complimentary strand) and the
sgRNA sequence was CACCGGGCACTGTGCCGAATGGCGG.
Compared to the target sequence CCGCCATTCGGCACAGTGCC
located on exon 2 near start codon, the MxB KO cells contained a
two base pair deletion CCG—ATTCGGCACAGTGCC. Interferon
treatment: Human Interferon Beta, 1a (PBL Assay Science) stock
was made in RPMI with glutaMAX (Life Technologies). Cells in 24-
well dishes were incubated with 500 ml medium containing either
no IFN-β, 100 U/ml or 1000 U/ml IFN-β, 25 ml virus dilution was
added 24 h later, the viral reporter activity was analyzed 72 h post
infection.
Monocyte derived macrophages (MDMs) and monocyte
derived dendritic cells (MDDCs) were generated by differentiation
of monocytes from human peripheral blood mononuclear cells
(PBMCs). Human buffy coats were obtained from “German Red
Cross Blood Donor Service Baden-Württemberg Hessen”. Primary
human monocytes were isolated from PBMCs by positive selection
for CD14þ cells using CD14-MicroBeads (Miltenyi Biotec, Bergisch
Gladbach, Germany; purity was 494%) according to themanufacturer's guidelines and separation from unlabeled cells was
carried out in AutoMACS device (Miltenyi Biotec). Subsequent
differentiation into M1-like MDM or MDDC was achieved by cul-
turing cells in RPMI-1640 containing 2 mM L-Glutamine, 10% FBS,
1% (v/v) HEPES, 1 mM sodium pyruvate, which was supplemented
with either 100 U/ml granulocyte-macrophage colony-stimulating
factor (GM-CSF) (PeproTech, Hamburg, Germany) or 500 U/ml
granulocyte-macrophage colony-stimulating factor (GM-CSF) and
1000 U/ml IL-4 (PeproTech) respectively. Medium change was
performed after three and six days, cells were used for subsequent
experiments on day seven. Stimulation of cells with cytokines was
done for 24 h in above mentioned media without the respective
differentiation cytokines but containing 2000 U/ml human Inter-
feron α2a/b, β1a (PBL Assay Science) or γ (PeproTech) or 10 ng/ml
CCL19, CXCL10 (PeproTech) or TNFα (Miltenyi Biotec).
Generation of viral vectors and infections
Reporter lentiviruses: Plasmid transfection into HEK293T cells
for lentiviral vectors was done with LipofectamineLTX (Life Tech-
nologies). For HIV-1, transfection experiments in 6-well dish
consist of 600 ng of the HIV-1 packaging constructs pMDLg/PRRE
(Dull et al., 1998), 250 ng of the HIV-1 Rev expression plasmid
pRSV-Rev (Dull et al., 1998), 600 ng of the HIV-1 reporter vector
pSIN.PPT.CMV.Luc.IRES.GFP, and 200 ng of the VSV-G expression
plasmid pMD.G (Emi et al., 1991). For HIV-2, transfection in 6-well
dish consists of 425 ng pHIV-2Δ4 (Morris et al., 2004), 125 ng
pMD.G, 300 ng HIV-2 Luc SV40, 300 ng pcDNA3.1. SIVagm and
SIVmac based reporter vectors were generated by transfection in
6-well plates with 1 mg pSIVAGM-luc E-R-Δvif or pSIVmac-luc E-
R-Δvif (Mariani et al., 2003), 200 ng pMD.G. EIAV luciferase vec-
tors were produced by transfection in 6-well dish with 1 mg
pONY3.1 (Mitrophanous et al., 1999), 1 mg pONY8.1luc (Zielonka
et al., 2009) and 250 ng pMD.G. FIV reporter vectors were pro-
duced by transfection in 6-well dish of 600 ng of pFP93 (Loewen et
al., 2003), a gift from Eric M. Poeschla, 600 ng of FIV-luciferase
vector pLiNSin (Münk et al., 2008), and 200 ng of pMD.G;
pcDNA3.1(þ) (Life Technologies) was used to ﬁll up to 2.2 mg total
DNA. Recombinant FV vector particles were harvested from tran-
siently transfected 293T cells as previously described (Hutter et al.,
2013; Mullers et al., 2011; Perkovic et al., 2009; Yap et al., 2008).
Brieﬂy, FV supernatants derived from the different production
systems were generated by polyethyleneimine (PEI)-mediated
cotransfection of HEK293T cells with the individual components of
the respective systems using 16 mg total DNA per 10-cm dish. For
the authentic 2-component vector system the transfer vector
(pcDWF002) and packaging vector Env (pcoSE) were mixed at a
ratio of 14:2. The packaging plasmids for the individual FV Gag
(e.g. pcoPG4, pcziSFVmac coGag), Pol (pcoPP) and Env (pcoSE) of
the expression-optimized four-component vector system as well
as the PFV transfer vector pMD11 were cotransfected at a ratio of
3.25:1.5:1:13. All packaged FV vector genomes harbored the
identical spleen focus forming virus (SFFV) U3 promoter-driven
LacZ reporter gene expression cassette. For infection assays,
4103 cells were transduced in 96-well plates in triplicate. Three
days post infection (dpi), luciferase activity was measured using
the Steadylite HTS kit (PerkinElmer, Rodgau, Germany) or
β-galactosidase activity by the Tropix Galacto-Star system (Life
Technologies). Data are presented as counts/s normalized to virus
obtained on cells that did not express Mx or were not treated with
interferon.
Quantitative PCR analysis
Preparation of particle samples, nucleic acid extraction and
qPCR or RT-qPCR analysis of viral particle nucleic acid composition
A. Bähr et al. / Virology 488 (2016) 51–60 59using Taqman primer probe sets speciﬁc for PFV LTR R-U5, PFV
integrase or human beta actin (hACTB) sequences was performed
as previously described (Hamann et al., 2014a, 2014b; Mullers
et al., 2011).
Immunoblots
Cells were lysed in radioimmunoprecipitation assay (RIPA)
buffer supplemented with Protease Inhibitors (Complete-Protease
Inhibitor Cocktail Tablets, Roche, Mannheim, Germany), 20–
30 min on ice. Lysates were clariﬁed by centrifugation (20 min,
14,000 pm, 4 °C). Samples were boiled (5 min 95 °C) in Roti-Load
(Roth, Karlsruhe, Germany) plus reducing agent and subjected to
SDS-PAGE followed by transfer to a PVDF membrane (Merck Mil-
lipore, Darmstadt, Germany). MxA protein was detected using an
anti-Mx antibody (M143 anti-Mx, mouse monoclonal, 1:1000
dilution, (Flohr et al., 1999)) this Ab recognizes MxA and MxB, MxB
was detected using anti-MxB speciﬁc Ab (N-17, sc-47197, goat,
polyclonal, Santa Cruz Biotechnology, Heidelberg, Germany,
1:1000 dilution), FLAG-MxA was detected using anti-FLAG ab (M2
antibody, mouse, monoclonal, Sigma-Aldrich, Munich, Germany,
1:1000 dilution). Tubulin was detected using anti-tubulin Ab
(DM1A, mouse, monoclonal, Sigma-Aldrich, 1:20,000 dilution),
GAPDH was detected using goat-anti-GAPDH Ab (EB06377, Everest
Biotech, 0.03 mg/ml), STAT1 was detected using anti-STAT1 Ab
(#sc346, rabbit, polyclonal, Santa Cruz; 1:5000 dilution), ERK was
detected using anti-p38 MAPK Antibody ERK1/2 (#9212, rabbit,
polyclonal, Cell Signaling Technology; 1:4000 dilution). Secondary
Abs: anti-mouse horseradish peroxidase (1:10,000 dilution,
NA931V, GE Healthcare, Solingen, Germany), anti-rabbit horse-
radish peroxidase (1:10,000 dilution, NA9340V, GE Healthcare)
and anti-goat horseradish peroxidase (rabbit, Sc-2768, Santa Cruz
Biotechnology, 1:10,000 dilution). Signals were visualized using
ECL prime reagent (GE Healthcare).
Statistical analysis
Data are represented as the mean with SD in all bar diagrams.
Statistically signiﬁcant differences between two groups were
analyzed using the unpaired Student's t-test with GraphPad Prism
version 5 (GraphPad software, San Diego, CA, USA). A minimum P
value of 0.05 was considered as statistically signiﬁcant: P
valueo0.001 extremely signiﬁcant (***), 0.001–0.01 very
signiﬁcant (**), 0.01–0.05 signiﬁcant (*), 40.05 not
signiﬁcant (ns).Acknowledgments
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